Transabdominal Gastric Contrast Ultrasound

NCT ID: NCT05596864

Last Updated: 2022-10-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-12-01
• Study Completion Date: 2024-12-30

Brief Summary

In this study, the clinical data of patients diagnosed with gastric cancer who were ready for surgery were examined by contrast-enhanced ultrasonography and gastric-enhanced CT before surgery. Based on the results of postoperative pathological examinations, the diagnostic accuracy of gastric filling contrast-enhanced ultrasonography and gastric contrast-enhanced CT in different stages of gastric cancer was compared and analyzed. Provide better guidance for follow-up clinical practice.

Conditions

Transabdominal Gastric Contrast Ultrasound

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Experimental group

Patients with gastric cancer underwent contrast-enhanced CT scan and gastric filling ultrasound, respectively.

gastric contrast ultrasound

Intervention Type: DIAGNOSTIC_TEST

Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.

In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed.

Interventions

gastric contrast ultrasound

Gastric contrast ultrasound (GCUS) refers to that the patient fills the stomach cavity with oral water, contrast agent and ultrasound contrast agent before the examination to remove the gas in the stomach cavity and fill the stomach cavity to become a homogeneous echo area and form a good acoustic sound. Interface contrast, more clearly showing the gastric wall hierarchy and the ultrasound examination method of the lesions.

In this way, not only the changes of the gastrointestinal mucosa can be found, but also the submucosal tumors of the gastrointestinal tract can be clearly displayed, the internal structural characteristics of the tumor, the extent of the lesions, the depth of infiltration, the TNM staging of the tumor, and the lesions of the surrounding organs can be displayed.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

1. Age: 18~80 years old, male or female;

2. Diagnosed with gastric cancer by histology or cytology;

3. No distant multiple metastasis;

4. ECOG score 0-2;

5. Heart, lung, liver and kidney function can tolerate surgery;

6. Patients and their families can understand and be willing to participate in this clinical study, and sign the informed consent.

Exclusion Criteria

1. Previous history of malignant tumor or recent diagnosis combined with other malignant tumors;

2. Patients with gastrointestinal perforation, gastrointestinal bleeding, etc. requiring emergency surgery;

3. Patients with previous gastroduodenal surgery;

4. Preoperative neoadjuvant therapy;

5. Patients and their families refuse surgical treatment;

6. ASA grade ≥ IV and/or ECOG performance status score > 2;

7. Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or combined with serious underlying diseases who cannot tolerate surgery;

8. Have a history of serious mental illness;

9. Pregnant or lactating women;

10. Patients with other clinical and laboratory conditions considered by the researchers should not participate in this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Hospital of Jilin University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wei Li, Prof.

Role: PRINCIPAL_INVESTIGATOR

The First Hospital of Jilin University

Central Contacts

Wei Li, Prof.

Role: CONTACT

weili8308@126.com

13596157865

Other Identifiers

CUS-GC

Identifier Type: -

Identifier Source: org_study_id